Corbus Pharmaceuticals has announced the release of an abstract for its first-in-human clinical study of CRB-701, indicating progress in its drug development pipeline. The upcoming poster ...
The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...
Corbus Pharmaceuticals Holdings ... Besides CRB-701, their pipeline includes other promising therapeutics such as CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ ... treatments in oncology and obesity by leveraging scientific innovation. Besides CRB-701, their pipeline includes other promising therapeutics such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback